Literature DB >> 34165252

Advancing to the era of cancer immunotherapy.

Yun Wang1,2, Min Wang1,2, Hao-Xiang Wu2,3, Rui-Hua Xu1,2.   

Abstract

Cancer greatly affects the quality of life of humans worldwide and the number of patients suffering from it is continuously increasing. Over the last century, numerous treatments have been developed to improve the survival of cancer patients but substantial progress still needs to be made before cancer can be truly cured. In recent years, antitumor immunity has become the most debated topic in cancer research and the booming development of immunotherapy has led to a new epoch in cancer therapy. In this review, we describe the relationships between tumors and the immune system, and the rise of immunotherapy. Then, we summarize the characteristics of tumor-associated immunity and immunotherapeutic strategies with various molecular mechanisms by showing the typical immune molecules whose antibodies are broadly used in the clinic and those that are still under investigation. We also discuss important elements from individual cells to the whole human body, including cellular mutations and modulation, metabolic reprogramming, the microbiome, and the immune contexture. In addition, we also present new observations and technical advancements of both diagnostic and therapeutic methods aimed at cancer immunotherapy. Lastly, we discuss the controversies and challenges that negatively impact patient outcomes.
© 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.

Entities:  

Keywords:  adverse effects; cancer; hyperprogressive disease; immune checkpoints; immunity; immunotherapy; metabolic reprogramming; microbiome; mutation

Year:  2021        PMID: 34165252     DOI: 10.1002/cac2.12178

Source DB:  PubMed          Journal:  Cancer Commun (Lond)        ISSN: 2523-3548


  21 in total

Review 1.  The theory of tumor ecosystem.

Authors:  Xueman Chen; Erwei Song
Journal:  Cancer Commun (Lond)       Date:  2022-06-01

Review 2.  Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.

Authors:  Jingjing Qu; Farhin Shaheed Kalyani; Li Liu; Tianli Cheng; Lijun Chen
Journal:  Cancer Commun (Lond)       Date:  2021-10-29

Review 3.  The Role of Gut Microbiota in Tumor Immunotherapy.

Authors:  Miao Wu; Jiawei Bai; Chengtai Ma; Jie Wei; Xianjin Du
Journal:  J Immunol Res       Date:  2021-08-26       Impact factor: 4.818

4.  Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis.

Authors:  Feng Wang; Ming-Ming He; Yi-Chen Yao; Xia Zhao; Zhi-Qiang Wang; Ying Jin; Hui-Yan Luo; Ji-Bin Li; Feng-Hua Wang; Miao-Zhen Qiu; Zhi-Da Lv; De-Shen Wang; Yu-Hong Li; Dong-Sheng Zhang; Rui-Hua Xu
Journal:  Cell Rep Med       Date:  2021-08-27

5.  Transcriptional suppression of CD8+ T cell exhaustion for improving T cell immunotherapy.

Authors:  Xue Yang; Bingjing Wang; Xuetao Cao
Journal:  Cancer Commun (Lond)       Date:  2021-09-23

6.  Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.

Authors:  Wenlong Zhong; Meng Yang; Sida Cheng; Weibin Hou; Bo Wang; Junyu Chen; Hao Yu; Yi Ouyang; Xiaofei Wang; Ziwei Ou; Peiqi Xu; Xuesong Li; Liqun Zhou; Jian Huang; Chunhui Wang; Tianxin Lin
Journal:  Cancer Sci       Date:  2022-01-14       Impact factor: 6.716

7.  Hotspots and Frontiers in Inflammatory Tumor Microenvironment Research: A Scientometric and Visualization Analysis.

Authors:  Yuli Zhang; Long Huo; Zhenzhen Wei; Qingfeng Tang; Hua Sui
Journal:  Front Pharmacol       Date:  2022-03-17       Impact factor: 5.810

8.  Reversing epigenetic repression of transposable elements for improving tumor immunogenicity.

Authors:  Xi Wang; Qian Zhang; Xuetao Cao
Journal:  Cancer Commun (Lond)       Date:  2022-01-09

Review 9.  Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice.

Authors:  Jinguo Zhang; Shuaikang Pan; Chen Jian; Li Hao; Jie Dong; Qingqing Sun; Hongwei Jin; Xinghua Han
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

10.  POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.

Authors:  Yan-Xing Chen; Zi-Xian Wang; Shu-Qiang Yuan; Teng-Jia Jiang; You-Sheng Huang; Rui-Hua Xu; Feng Wang; Qi Zhao
Journal:  Clin Transl Med       Date:  2021-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.